drugset / Trial / NCT02154776

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

NCT02154776

Phase 1 Completed 13 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

This is a multi-center, open-label, non-randomized, phase I study

Timeline

Start
2014-06-27
Primary completion
2016-10-26
Completion
2016-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Buparlisib Small molecule
Subject Letrozole Other / unclassified 2.5 mg
Subject Ribociclib Small molecule

Indications